secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093945
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q2 net loss $50.8M; cash $491.5M; ziftomenib pivotal data expected early 2025
--------------------------------------------------------------------------------

- Net loss $50.8M in Q2 2024 vs $37.2M in Q2 2023; R&D expenses $39.7M vs $28.2M.
- Cash, equivalents & short-term investments $491.5M at June 30, 2024; runway into 2027.
- Ziftomenib completed enrollment of 85 patients in KOMET-001 pivotal trial; FDA Breakthrough Therapy Designation; topline data early 2025.
- Phase 1b expansion of KOMET-007 (ziftomenib + ven/aza and 7+3) now enrolling; data expected Q4 2024.
- IND cleared for ziftomenib in GIST; proof-of-concept study with imatinib planned H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017024093945/0000950170-24-093945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017024093945/kura-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer